Lamotrigine as a mood stabilizer: insights from the pre-clinical evidence

Página do item simplificado
dc.creatorAline Silva de Miranda
dc.creatorAmanda Silva de Miranda
dc.creatorAntonio Lucio Teixeira Junior
dc.date.accessioned2022-11-10T23:34:31Z
dc.date.accessioned2025-09-08T22:53:31Z
dc.date.available2022-11-10T23:34:31Z
dc.date.issued2019
dc.description.sponsorshipCNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológico
dc.description.sponsorshipFAPEMIG - Fundação de Amparo à Pesquisa do Estado de Minas Gerais
dc.identifier.doihttps://doi.org/10.1080/17460441.2019.1553951
dc.identifier.issn17460441
dc.identifier.urihttps://hdl.handle.net/1843/47164
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofExpert Opinion on Drug Discovery
dc.rightsAcesso Restrito
dc.subjectTranstorno bipolar
dc.subjectDepressão mental
dc.subjectDopamina
dc.subjectGlutamato monossódico
dc.subjectSerotonina
dc.subjectDistúrbios cognitivos
dc.subjectModelos animais
dc.subject.otherLamotrigine
dc.subject.otherBipolar depression
dc.subject.otherDisorder bipolar
dc.subject.otherMania
dc.subject.otherSerotonin
dc.subject.otherDopamine
dc.subject.otherGlutamate
dc.subject.otherBDNF
dc.subject.otherBcl-2
dc.subject.otherAnimal models
dc.titleLamotrigine as a mood stabilizer: insights from the pre-clinical evidence
dc.typeArtigo de periódico
local.citation.epage190
local.citation.issue2
local.citation.spage179
local.citation.volume14
local.description.resumoIntroduction: Lamotrigine (LTG) is a well-established anticonvulsant that is also approved for the prevention of mood relapses in bipolar disorder. However, the mechanisms underlying LTG mood stabilizing effects remain unclear. Areas covered: Herein, the pre-clinical evidence concerning LTG’s’ mode of action in depression and mania is reviewed. Bottlenecks and future perspectives for this expanding and promising field are also discussed. Pre-clinical studies have indicated that neurotransmitter systems, especially serotoninergic, noradrenergic and glutamatergic, as well as non-neurotransmitter pathways such as inflammation and oxidative processes might play a role in LTG’s antidepressant effects. The mechanisms underlying LTG’s anti-manic properties remain to be fully explored, but the available pre-clinical evidence points out to the role of glutamatergic neurotransmission, possibly through AMPA-receptors. Expert opinion: A major limitation of current pre-clinical investigations is that there are no experimental models that recapitulate the complexity of bipolar disorder. Significant methodological differences concerning time and dose of LTG treatment, administration route, animal strains, and behavioral paradigms also hamper the reproducibility of the findings, leading to contradictory conclusions. Moreover, the role of other mechanisms (e.g. inositol phosphate and GSK3β pathways) implicated in the mode of action of different mood-stabilizers must also be consolidated with LTG.
local.identifier.orcidhttps://orcid.org/0000-0003-2811-7924
local.identifier.orcidhttps://orcid.org/0000-0002-8887-2772
local.identifier.orcidAntonio Lucio Teixeira Junior
local.publisher.countryBrasil
local.publisher.departmentICB - DEPARTAMENTO DE MORFOLOGIA
local.publisher.departmentICX - DEPARTAMENTO DE QUÍMICA
local.publisher.departmentMED - DEPARTAMENTO DE CLÍNICA MÉDICA
local.publisher.initialsUFMG
local.url.externahttps://www.tandfonline.com/doi/abs/10.1080/17460441.2019.1553951?journalCode=iedc20

Arquivos

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG